N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=18 Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)
Hepatitis, Viral, Human
Primary: Mean Reduction From Baseline in Log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 5 - HCV GT1 — 4.25; 4.40; 3.56; 0.00 IU/mL
Phase 2 N=49 Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
Malignant Solid Tumour · Gastroesophageal Cancer
Primary: The Incidence of Dose Limiting Toxicities (DLT) in Phase I Dose Escalation — 0; 0; 1 participants
Phase 2 N=24 Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval at Steady State — 87.14; 85.15 pg*hr/mL
N/A N=20 Acupuncture for Reduction of Inflammation
Thyroid or Parathyroid Surgery
Primary: Reduced Pain Medication Requirement — 5.43; 7.36 mg of Morphine
N/A N=382 Assessment of Novel Respiratory Protective Devices in Healthcare
Comfort · Tolerability
Primary: To Collect Healthcare Worker Feedback About Perceived Comfort of Novel Respirator Designs — 5.0; 4.6; 3.7; 4.0 units on a scale
Phase 1 N=90 Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
Acanthamoeba Keratitis
Primary: Number of Subjects With Dose-limiting Adverse Events — 0; 2; 3; 0 participants
Phase 2 N=238 Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
Head and Neck Cancer
Primary: Disease-free Survival — 57.3; 65.9 percentage of participants — p=0.05
Phase 4 N=39 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Chronic Phase Chronic Myeloid Leukemia
Primary: The Number of Imatinib-related Adverse Events (AEs) That Were Resolved, Improved, Remained Unchanged, or Worsened After 3 Months of Dasatinib Treatment — 91; 2; 27; 1…
N/A N=200 SEEQ™ Performance Study
Arrhythmia Type Unknown
Primary: Diagnostic Yield of the SEEQ™ MCT/ECM System — 85.7 percentage of subjects with CRA
Phase 2 N=260 Surgical Ablation Versus No Surgical Ablation for Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery
Atrial Fibrillation · Mitral Valve Insufficiency · Mitral Valve Stenosis
Primary: Freedom From Atrial Fibrillation — 31.1; 61.8 percentage of patients
Phase 1 N=31 Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
Chronic Hepatitis C Infection
Primary: Effect of HSV-2 Suppression on HCV Viral Load. — .18; .03 log(IU/mL)
N/A N=36 Exercise,Metabolic Syndrome and Weight Regain (Echocardiography Substudy)
Metabolic Syndrome · Obesity
Primary: Mean Resting E/E' — 7.01 ml/min/kg — p==0.14
Phase 3 N=44 Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management
Overweight · Obese
Primary: Change in Waist Circumference — -2.3; -6.0; -4.0 cm — p=0.398
N/A N=16 HAART Model 300 Annuloplasty Ring
Aortic Regurgitation
Primary: Primary Safety Outcome Measure: Event-free Survival — 100 percentage of participants